- Home
- VTVT vs CIK Comparison
VTVT vs CIK Comparison
Compare VTVT & CIK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VTVT | CIK |
|---|---|---|
| Founded | 2015 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 143.7M | 156.2M |
| IPO Year | 2015 | 1995 |
Fundamental Metrics
Financial Performance| Metric | VTVT | CIK |
|---|---|---|
| Price | $35.77 | $2.62 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $55.25 | N/A |
| AVG Volume (30 Days) | 27.0K | ★ 383.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $1,017,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.00 | $2.56 |
| 52 Week High | $44.00 | $3.01 |
Technical Indicators
Market Signals| Indicator | VTVT | CIK |
|---|---|---|
| Relative Strength Index (RSI) | 48.13 | 18.47 |
| Support Level | $31.42 | N/A |
| Resistance Level | $42.71 | $3.00 |
| Average True Range (ATR) | 3.35 | 0.03 |
| MACD | -0.11 | -0.01 |
| Stochastic Oscillator | 19.78 | 0.00 |
Price Performance
Historical ComparisonAbout VTVT vTv Therapeutics Inc.
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin, currently in a Phase 3 trial, a potential novel first-in-class oral liver-selective glucokinase activator being investigated for the treatment of type 1 diabetes. The group and its development partners are investigating multiple molecules across different indications for chronic diseases. Its product pipeline are HPP737, Azeliragon, TTP-RA, TTP273, HPP971 / HPP3033, and HPP593.
About CIK Credit Suisse Asset Management Income Fund Inc.
Credit Suisse Asset Mgmt Income Fund Inc is a closed-end management investment company. The investment objective of the fund is to provide current income consistent with the preservation of capital. Credit Suisse serves as an investment adviser for the fund. Asset Management offers a wide range of investment products and functions across asset classes and investment styles. The division manages various regional portfolios, mutual funds, and other investment vehicles for governments, institutions, corporations and individuals.